Stryker (NYSE:SYK) Now Covered by Analysts at Rothschild & Co Redburn

Rothschild & Co Redburn initiated coverage on shares of Stryker (NYSE:SYK) in a report published on Thursday, Marketbeat reports. The brokerage issued a neutral rating and a $420.00 price target on the medical technology company’s stock.

Several other research analysts also recently weighed in on the stock. Citigroup reissued a “buy” rating and issued a $455.00 target price (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Truist Financial set a $415.00 price objective on shares of Stryker and gave the stock a “hold” rating in a research report on Monday, August 4th. Needham & Company LLC increased their target price on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Wells Fargo & Company lifted their price target on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Finally, BTIG Research reissued a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $430.33.

Stryker Stock Up 0.3%

SYK stock opened at $377.92 on Thursday. The firm has a market cap of $144.48 billion, a PE ratio of 50.06, a P/E/G ratio of 2.71 and a beta of 0.93. Stryker has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm has a 50 day simple moving average of $387.77 and a 200 day simple moving average of $379.28.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts forecast that Stryker will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio is 44.50%.

Insider Buying and Selling at Stryker

In related news, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Institutional Trading of Stryker

A number of institutional investors and hedge funds have recently modified their holdings of SYK. Capital A Wealth Management LLC acquired a new position in shares of Stryker in the 4th quarter valued at $26,000. Mid American Wealth Advisory Group Inc. bought a new stake in Stryker in the second quarter valued at about $26,000. Elevation Point Wealth Partners LLC bought a new stake in Stryker in the second quarter valued at about $28,000. Sachetta LLC lifted its stake in Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the period. Finally, Kilter Group LLC acquired a new stake in Stryker during the second quarter valued at approximately $29,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.